Stock market today: S&P 500 drops for fifth day as focus shifts to Powell’s speech
Investing.com - Stifel has reiterated its Buy rating and $12.00 price target on Nyxoah SA (NASDAQ:NYXH), with the firm focusing on the company’s recent FDA approval rather than its preannounced second-quarter 2025 results. According to InvestingPro data, analyst targets range from $11.99 to $14.08, suggesting significant upside potential from the current price of $6.57.
The research firm notes that Nyxoah’s launch plans will target high-volume centers, specifically the approximately 300 U.S. HGNS facilities that represent about 75% of the industry’s volume. While the company maintains a strong liquidity position with a current ratio of 3.59 and more cash than debt on its balance sheet, InvestingPro analysis indicates rapid cash burn requires careful monitoring.
Stifel’s survey research indicates strong interest among ENT specialists to receive training on Nyxoah’s Genio device, which offers potential advantages over competing products, including an external power source and no implantable in the chest wall.
The firm projects Genio will capture 2.1% of the U.S. market share in 2026, increasing to 10.5% by 2028 and reaching mid-to-high teens by 2029-2030, similar to the share Nyxoah has achieved in the German market.
Stifel also expects Nyxoah to benefit from on-label CCC (WA:CCCP) U.S. tailwinds beginning in 2027, which could help address pent-up demand for the company’s products.
In other recent news, Nyxoah SA reported strong revenue growth for the second quarter of 2025, despite incurring an operating loss. The company highlighted strategic advancements and received FDA approval for its GENIOR system, which is a significant development. These announcements contributed to a notable increase in Nyxoah’s stock following the earnings release. The FDA approval is seen as a positive step for the company in expanding its market presence. Investors appear optimistic about Nyxoah’s future prospects due to these recent developments. The company’s focus on innovative solutions for obstructive sleep apnea continues to drive its growth strategy. While the operating loss remains a concern, the revenue growth and regulatory milestones are encouraging signs. Analysts are watching Nyxoah closely as it navigates these changes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.